Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms ASSURE; ASSURE-1
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
    • 30 Aug 2017 Results assessing impact of apabetalone on attenuated coronary atherosclerotic plaque presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top